Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | ||
Feb. 28, 2014 | Jun. 12, 2014 | Aug. 31, 2013 | |
Document Type | '10-K | ' | ' |
Amendment Flag | 'false | ' | ' |
Document Period End Date | 28-Feb-14 | ' | ' |
Trading Symbol | 'pedx | ' | ' |
Entity Registrant Name | 'QUINT MEDIA INC. | ' | ' |
Entity Central Index Key | '0001362703 | ' | ' |
Current Fiscal Year End Date | '--02-28 | ' | ' |
Entity Filer Category | 'Smaller Reporting Company | ' | ' |
Entity Common Stock, Shares Outstanding | ' | 62,883,000 | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Voluntary Filers | 'No | ' | ' |
Entity Well Known Seasoned Issuer | 'No | ' | ' |
Entity Public Float | ' | ' | $8,513,700 |
Document Fiscal Year Focus | '2014 | ' | ' |
Document Fiscal Period Focus | 'FY | ' | ' |
Balance_Sheets
Balance Sheets (USD $) | Feb. 28, 2014 | Feb. 28, 2013 |
Current Assets | ' | ' |
Cash and cash equivalents | $12,957 | $512,484 |
Prepaid expenses | 4,928 | 22,635 |
Total Current Assets | 17,885 | 535,119 |
Website and website development cost, net of amortization of $17,440 and $0, respectively | 331,360 | 0 |
Assets from discontinued operations | 0 | 250,556 |
Total Assets | 349,245 | 785,675 |
Current Liabilities | ' | ' |
Accounts payable and accrued liabilities | 106,046 | 104,728 |
Accounts payable and accrued liabilities, related party | 304,588 | 0 |
Short-term notes payable | 450,000 | 500,000 |
Liabilities from discontinued operations | 109,449 | 119,382 |
Total Liabilities | 970,083 | 724,110 |
Stockholders' Equity (Deficit) | ' | ' |
Common stock, 450,000,000 shares authorized, par value $0.0001, 62,883,000 and 62,508,000 shares issued and outstanding at February, 28, 2014 and 2013, respectively | 6,288 | 6,251 |
Additional paid-in capital | 2,697,541 | 2,622,578 |
Deficit accumulated during the development stage | -3,324,667 | -2,567,264 |
Total Stockholders' Equity (Deficit) | -620,838 | 61,565 |
Total Liabilities and Stockholders' Equity (Deficit) | $349,245 | $785,675 |
Balance_Sheets_Parenthetical
Balance Sheets (Parenthetical) (USD $) | Feb. 28, 2014 | Feb. 28, 2013 |
Accumulated Amortization of Website Development Costs | $17,440 | $0 |
Common Stock, Shares Authorized | 450,000,000 | 450,000,000 |
Common Stock, Par Value Per Share | $0.00 | $0.00 |
Common Stock, Shares, Issued | 62,883,000 | 62,508,000 |
Common Stock, Shares, Outstanding | 62,883,000 | 62,508,000 |
Statement_of_Operations
Statement of Operations (USD $) | 12 Months Ended | 107 Months Ended | |
Feb. 28, 2014 | Feb. 28, 2013 | Feb. 28, 2014 | |
Net Revenues | $24 | $0 | $24 |
Expenses | ' | ' | ' |
Website operations and maintenance | 52,093 | 0 | 52,093 |
Website amortization | 17,440 | 0 | 17,440 |
Professional fees | 266,610 | 153,576 | 266,610 |
General and administrative | 198,087 | 169,910 | 198,087 |
Total Expenses | 534,230 | 323,486 | 534,230 |
Other Expenses | ' | ' | ' |
Interest Expense | -31,716 | -45,828 | -31,716 |
Net Loss From Continuing Operations | -565,922 | -369,314 | -565,922 |
Income (Loss) From Discontinued Operations | -191,481 | 53,376 | -2,758,745 |
Net Loss | ($757,403) | ($315,938) | ($3,324,667) |
Basic and diluted loss per common share from continuing operations | ($0.01) | ($0.01) | ' |
Basic and diluted income (loss) per common share from discontinued operations | $0 | $0 | ' |
Basic and diluted income (loss) per common share | ($0.01) | ($0.01) | ' |
Weighted average number of common shares | 62,605,603 | 62,508,508 | ' |
Statement_of_Cash_Flows
Statement of Cash Flows (USD $) | 12 Months Ended | 107 Months Ended | |
Feb. 28, 2014 | Feb. 28, 2013 | Feb. 28, 2014 | |
Cash Flows From Operating Activities | ' | ' | ' |
Net loss | ($757,403) | ($315,938) | ($3,324,667) |
Items to reconcile net loss to net cash used in operating activities: | ' | ' | ' |
Amortization | 17,440 | 0 | 17,440 |
Contributions to capital by related parties - expenses | 0 | 0 | 58,799 |
Contributions to capital by related party - forgiveness of debt | 0 | 0 | 38,950 |
Common shares issued for services | 0 | 0 | 30 |
Stock based compensation | 0 | 132,138 | 346,050 |
(Increase) decrease in prepaid expenses and deposits | 17,707 | -4,294 | -4,928 |
Increase in accounts payable and accrued liabilities, related party | 108,088 | 0 | 108,088 |
Increase (decrease) in accounts payable and accrued liabilities | 1,318 | -158,850 | 222,961 |
Net cash used in continuing operations | -612,850 | -346,944 | -2,537,277 |
Net cash provided by (used in) discontinued operations | 240,623 | -290,677 | 45,669 |
Net cash used in operating activities | -372,227 | -637,621 | -2,491,608 |
Cash Flows From Investing Activities | ' | ' | ' |
Acquisition of SlickX and Flawsome | -50,000 | 0 | -50,000 |
Capitalized website and website development costs | -102,300 | 0 | -102,300 |
Net cash used in continuing investing activities | -152,300 | 0 | -152,300 |
Net cash provided (used) in discontinued investing activities | 0 | 891,965 | -53,135 |
Net cash provided by (used in) investing activities | -152,300 | 891,965 | -205,435 |
Cash Flows From Financing Activities | ' | ' | ' |
Proceeds from issuance of promissory notes | 150,000 | 0 | 855,000 |
Principal payments on promissory notes | -200,000 | 0 | -200,000 |
Common shares returned to treasury | 0 | 0 | -5,000 |
Proceeds from issuance of common stock | 75,000 | 0 | 2,060,000 |
Cash provided by (used in) financing activities | 25,000 | 0 | 2,710,000 |
Increase (decrease) in cash and cash equivalents | -499,527 | 254,344 | 12,957 |
Cash and cash equivalents, beginning of period | 512,484 | 258,140 | 0 |
Cash and cash equivalents, end of period | 12,957 | 512,484 | 12,957 |
Noncash investing activity | ' | ' | ' |
Capitalized website and website development costs | 196,500 | 0 | 196,500 |
Apricus Biosciences, Inc. common stock received in consideration for termination of merger agreement | $0 | $1,000,000 | $1,000,000 |
Statements_of_Stockholders_Equ
Statements of Stockholders Equity (USD $) | Capital Stock [Member] | Additional Paid-In Capital [Member] | Deficit, accumlated during the development stage [Member] | Total |
Beginning Balance at Mar. 18, 2005 | ' | ' | ' | ' |
Restricted common shares issued for cash September 2005 | $3,000 | $2,000 | ' | $5,000 |
Restricted common shares issued for cash September 2005 (Shares) | 30,000,000 | ' | ' | ' |
Contributions to capital by related parties expenses | ' | 600 | ' | 600 |
Net loss for the year | ' | ' | -21,237 | -21,237 |
Ending Balance at Feb. 28, 2006 | 3,000 | 2,600 | -21,237 | -15,637 |
Ending Balance (Shares) at Feb. 28, 2006 | 30,000,000 | ' | ' | ' |
Common shares issued for cash ($0.005 per share) May 2006 | 3,000 | 47,000 | ' | 50,000 |
Common shares issued for cash ($0.005 per share) May 2006 (Shares) | 30,000,000 | ' | ' | ' |
Common shares issued for services ($0.005 per share) August 2006 and February 2007 | 2 | 28 | ' | 30 |
Common shares issued for services ($0.005 per share) August 2006 and February 2007 (Shares) | 18,000 | ' | ' | ' |
Contributions to capital by related parties expenses | ' | 11,400 | ' | 11,400 |
Net loss for the year | ' | ' | -50,890 | -50,890 |
Ending Balance at Feb. 28, 2007 | 6,002 | 61,028 | -72,127 | -5,097 |
Ending Balance (Shares) at Feb. 28, 2007 | 60,018,000 | ' | ' | ' |
Contributions to capital by related parties expenses | ' | 14,400 | ' | 14,400 |
Common shares returned and cancelled for cash April 2007 | -300 | -4,700 | ' | -5,000 |
Common shares returned and cancelled for cash April 2007 (Shares) | -3,000,000 | ' | ' | ' |
Common shares issued for cash May 2007 | 300 | 4,700 | ' | 5,000 |
Common shares issued for cash May 2007 (Shares) | 3,000,000 | ' | ' | ' |
Net loss for the year | ' | ' | -65,411 | -65,411 |
Ending Balance at Feb. 29, 2008 | 6,002 | 75,428 | -137,538 | -56,108 |
Ending Balance (Shares) at Feb. 29, 2008 | 60,018,000 | ' | ' | ' |
Contributions to capital by related parties expenses | ' | 14,400 | ' | 14,400 |
Contributions to capital by related parties loan forgiveness | ' | 38,950 | ' | 38,950 |
Common shares issued for cash November 2008 | 150 | 49,850 | ' | 50,000 |
Common shares issued for cash November 2008 (Shares) | 1,500,000 | ' | ' | ' |
Net loss for the year | ' | ' | -53,957 | -53,957 |
Ending Balance at Feb. 28, 2009 | 6,152 | 178,628 | -191,495 | -6,715 |
Ending Balance (Shares) at Feb. 28, 2009 | 61,518,000 | ' | ' | ' |
Contributions to capital by related parties expenses | ' | 14,399 | ' | 14,399 |
Net loss for the year | ' | ' | -58,201 | -58,201 |
Ending Balance at Feb. 28, 2010 | 6,152 | 193,027 | -249,696 | -50,517 |
Beginning Balance (Shares) at Feb. 28, 2010 | 61,518,000 | ' | ' | ' |
Contributions to capital by related parties expenses | ' | 3,600 | ' | 3,600 |
Common shares issued for cash June 2010 | 450 | 299,550 | ' | 300,000 |
Common shares issued for cash June 2010 (Shares) | 4,500,000 | ' | ' | ' |
Common shares issued for cash July 2010 | 450 | 749,550 | ' | 750,000 |
Common shares issued for cash July 2010 (Shares) | 4,500,000 | ' | ' | ' |
Common shares issued for cash November 2010 | 248 | 824,752 | ' | 825,000 |
Common shares issued for cash November 2010 (Shares) | 2,475,000 | ' | ' | ' |
Common shares returned and cancelled November 2010 | -1,110 | 1,110 | ' | ' |
Common shares returned and cancelled November 2010 (Shares) | -11,100,000 | ' | ' | ' |
Common shares issued for debt cancellation November 2010 | 61 | 204,939 | ' | 205,000 |
Common shares issued for debt cancellation November 2010 (Shares) | 615,000 | ' | ' | ' |
Net loss for the year | ' | ' | -1,049,087 | -1,049,087 |
Ending Balance at Feb. 28, 2011 | 6,251 | 2,276,528 | -1,298,783 | 983,996 |
Ending Balance (Shares) at Feb. 28, 2011 | 62,508,000 | ' | ' | ' |
Stock based compensation | ' | 213,912 | ' | 213,912 |
Net loss for the year | ' | ' | -952,543 | -952,543 |
Ending Balance at Feb. 29, 2012 | 6,251 | 2,490,440 | -2,251,326 | 245,365 |
Ending Balance (Shares) at Feb. 29, 2012 | 62,508,000 | ' | ' | ' |
Stock based compensation | ' | 132,138 | ' | 132,138 |
Net loss for the year | ' | ' | -315,938 | -315,938 |
Ending Balance at Feb. 28, 2013 | 6,251 | 2,622,578 | -2,567,264 | 61,565 |
Beginning Balance (Shares) at Feb. 28, 2013 | 62,508,000 | ' | ' | ' |
Common shares issued for cash November 2013 | 37 | 74,963 | ' | 75,000 |
Common shares issued for cash November 2013 (Shares) | 375,000 | ' | ' | ' |
Stock based compensation | ' | ' | ' | 0 |
Net loss for the year | ' | ' | -757,403 | -757,403 |
Ending Balance at Feb. 28, 2014 | $6,288 | $2,697,541 | ($3,324,667) | ($620,838) |
Ending Balance (Shares) at Feb. 28, 2014 | 62,883,000 | ' | ' | ' |
Nature_of_Operations_and_Conti
Nature of Operations and Continuance of Business | 12 Months Ended | |
Feb. 28, 2014 | ||
Nature of Operations and Continuance of Business [Text Block] | ' | |
1 | Nature of Operations and Continuance of Business | |
Quint Media, Inc. (formerly PediatRx Inc.) (the “Company” or “Quint”) was incorporated under the laws of the State of Nevada on March 18, 2005. The Company originally intended to engage in the acquisition and exploration of mineral properties. From the date of its acquisition of Granisol ® (granisetron #C1) oral solution (“Granisol”), on July 23, 2010, until early fiscal year 2014, Quint engaged in the pharmaceutical business. During the fiscal year ending February 28, 2014, Quint decided to divest itself of the balance of its pharmaceutical assets and engage in the digital media business. | ||
Quint is in the process of transitioning to its new operating business, digital media. The digital media business encompasses entrance into the social discovery aspects of the internet, primarily through the development of an engagement website with mobile and tablet applications. Quint capitalizes costs of licenses for the use of Internet domain names or Universal Resource Locators, website development costs, other information technology licenses and marketing and technology related intangibles. All such assets are capitalized at their original cost and upon substantial completion, are amortized over their estimated useful lives. | ||
PediatRx Inc. was incorporated under the laws of the State of Nevada on March 18, 2005. The Company originally intended to engage in the acquisition and exploration of mineral properties. | ||
On June 17, 2010, the Company entered into a letter of intent with Cypress Pharmaceutical, Inc. ("Cypress") to acquire all of the assets associated with Granisol® (granisetron HC1) oral solution ("Granisol"). First approved in 2008, Granisol is an oral, liquid granisetron solution, formerly distributed by Hawthorn Pharmaceuticals, a subsidiary of Cypress. The Food and Drug Administration has approved Granisol's use in cancer care to treat nausea and vomiting associated with cancer therapy. On June 18, 2010, the Company caused PediatRx Inc. ("PediatRx") to be incorporated as a wholly-owned subsidiary of Striker Energy Corp. ("Striker") under the laws of the state of Nevada. On July 23, 2010, the Company concluded a definitive agreement to acquire Granisol from Cypress and turned its focus to the pharmaceutical industry and terminated its interest in oil and natural gas exploration. | ||
On December 28, 2010 the Company completed a merger of PediatRx into Striker Energy Corp. and changed the name of Striker Energy Corp. to PediatRx Inc. | ||
On September 12, 2011 the Company entered into a co-promotion agreement with Bi-Coastal Pharmaceutical Corp. ("Bi- Coastal"). Pursuant to the co-promotion agreement, Bi-Coastal granted the Company the non- exclusive right to promote Aquoral™ within the United States of America. Aquoral, another oncology supportive care product, is an FDA-cleared treatment for xerostomia (the medical term for dry mouth due to a lack of saliva). Xerostomia is especially prevalent in patients undergoing various treatments for cancer and those with Sjogren's syndrome. The Company was required to include Aquoral in no less than 85% of its sales calls. In return for its promotional efforts, the Company would receive compensation for each unit sold. The agreement with Bi-Coastal was for an initial term of two years and would automatically renew for one year terms unless either party provides notice of non-renewal at least six months prior to the expiration of the then- current term. The agreement was terminable at any time, by either party, upon six months prior written notice to the other party and is also terminable for cause. | ||
On January 26, 2012, the Company entered into a binding term sheet (the "Term Sheet") with Apricus Biosciences, Inc. ("Apricus") for (1) a Co-Promotion Agreement in the United States for Granisol (the "Co- Promotion Agreement"), (2) the assignment of its Co-Promotion Agreement with Bi-Coastal for Aquoral™ to Apricus (the "Assignment Agreement”) and (3) a Sale Agreement for Granisol outside of the United States (the "Asset Purchase Agreement"). Also in the Term Sheet, the Company entered into a non-binding arrangement (the "Arrangement") for the sale of the Company to Apricus in a proposed merger transaction (the "Acquisition"). | ||
In February 21, 2012 the Company entered into three definitive agreements and one side letter with Apricus which include the Co-Promotion Agreement, the Assignment Agreement and the Asset Purchase Agreement. Pursuant to the Co- Promotion Agreement, the Company granted to Apricus the exclusive right to commercialize Granisol in six U.S. states and the non-exclusive right to commercialize Granisol in all other U.S. States, in addition to the right to manufacture Granisol. In addition, the Company agreed that, for a period of five years from the effective date of the Co-Promotion Agreement, it would not license any co-promotion rights in the non-exclusive states to any third party. The Company retained the right to commercialize Granisol in the non-exclusive states. The Company recognizes sales in the non-exclusive states that it generates through its own promotional efforts. Each party has agreed to cooperate with the other in respect of promotional materials and efforts on terms specified in the Co-Promotion Agreement. | ||
The initial term of the Co-Promotion Agreement was for a period of ten years from the effective date, though it may be terminated prior to expiration under certain conditions. If the Co-Promotion Agreement was terminated by the Company prior to the end of the initial term, the Company would be required to pay to Apricus an amount based upon a varying percentage of its net operating income related to Granisol for a period subsequent to termination depending upon when the termination occurs. | ||
Pursuant to the Assignment Agreement, the Company assigned all of its rights and responsibilities under the Co-Promotion agreement with Bi-Coastal for Aquoral, and Apricus assumed all rights and responsibilities under the Co-Promotion Agreement as of the effective date. Bi-Coastal consented to the assignment of the co-promotion agreement. | ||
Pursuant to the Asset Purchase Agreement, the Company sold to Apricus all of its rights related to Granisol in all countries and territories outside of the United States. The Company agreed that it and its officers and directors would not compete in the field of anti-emetic products in certain areas outside of the United States. | ||
As consideration for entering into these three Agreements the Company received an initial payment of $325,000 from Apricus. The agreements also provided for the payment to the Company of a royalty that would be calculated based upon Apricus' United States generated net operating income related to Granisol. On the effective date of the Agreements, the Company recognized revenues of $260,000 associated with the exclusive rights for Apricus to commercialize Granisol in six U.S. states. In addition, the Company has recognized a gain from sale of product rights totaling $65,000 associated with the Asset Purchase Agreement. | ||
The binding term sheet between the Company and Apricus contemplated, in addition to the transactions reflected in the three agreements described above, a non-binding expression of interest in the merger of the Company with Apricus. The non-binding portion of the term sheet contemplated that the Company would be acquired by Apricus in a merger in exchange for $4,000,000, to be paid in the common stock of Apricus, with $3,600,000 distributed to the shareholders of the Company immediately and $400,000 held back from shares that would be distributed to the Company's Chief Executive Officer and Chief Financial Officer for a period of six months as an indemnity for breaches by the Company of its representations and warranties. Additionally, it contemplates that Apricus would assume certain debt and liabilities of the Company up to $675,000. The side letter referred to above refines the timing with respect to the parties' agreement that Apricus will pay to the Company a 'break-up fee" (in the form of restricted stock of Apricus having a value of $1,000,000) if the two companies did not merge by June 1, 2012, (or such other date as may be mutually agreed to by the Parties) unless, prior to that date, the Company files for bankruptcy or the Granisol asset is materially impaired. | ||
On June 27, 2012, the Company entered into a Termination Agreement (the “Termination Agreement”) with Apricus Biosciences, Inc. (“Apricus”) pursuant to which the parties acknowledged that they formally terminated discussions regarding the proposed merger of the two companies. | ||
Pursuant to the Termination Agreement, Apricus issued and delivered to us 373,134 shares of its common stock in full satisfaction of its obligation to pay us $1,000,000 in common stock as a break-up fee. The Company has recognized other income of $1,000,000 related to the break-up fee. | ||
In addition, pursuant to the Termination Agreement, on July 16, 2012, Apricus filed a Registration Statement on Form S-3 registering these shares for resale, which the Registration Statement was declared effective by the Securities and Exchange Commission on October 3, 2012. The Company has agreed that if it proposes to sell any of the shares on a public market or quotation service, it will only be permitted to sell on any given trading day, such number of shares as does not exceed 5% of the average daily volume of the Apricus’ common stock traded in the previous five trading days. Due to the sales restrictions, the Company determined the fair value using quoted prices for similar assets in active markets that are directly observable and thus represent a Level 2 fair value measurement. The fair value of the investment in Apricus was $1,000,000 at the effective date. The Company has sold all of its shares of Apricus stock. | ||
Effective August 7, 2013, Quint affected a three-for-one forward stock split of our authorized, and issued and outstanding shares of common stock. Authorized common stock increased from 150,000,000 shares of common stock to 450,000,000 shares of common stock, and issued and outstanding capital increased from 20,836,000 shares of common stock to 62,508,000 shares of common stock. All references to Quint common stock have been retroactively restated to reflect the effect of the forward split. | ||
The Company is a development stage enterprise, as defined in Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 915, Development Stage Entities . Quint is in the process of transitioning to its new operating business, primarily development of its engagement website with mobile and tablet application. |
Summary_of_Significant_Account
Summary of Significant Accounting Policies | 12 Months Ended | |||||||
Feb. 28, 2014 | ||||||||
Summary of Significant Accounting Policies [Text Block] | ' | |||||||
2 | Summary of Significant Accounting Policies | |||||||
a. Basis of Presentation and Accounting Methods | ||||||||
The financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States using the accrual method of accounting. The Company’s fiscal year-end is February 28. | ||||||||
b. Use of Estimates | ||||||||
The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. | ||||||||
c. Reclassification | ||||||||
Certain prior year amounts have been reclassified to conform to the current year presentation. | ||||||||
d. Cash and Cash Equivalents | ||||||||
The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. As of February 28, 2014 and 2013, the Company had no cash equivalents. | ||||||||
e. Intangible Assets | ||||||||
Acquired intangible assets other than goodwill are amortized over their useful lives unless the lives are determined to be indefinite. Acquired intangible assets are carried at cost, less accumulated amortization. For intangible assets purchased in a business combination or received in a non-monetary exchange, the estimated fair values of the assets received (or, for non-monetary exchanges, the estimated fair values of the assets transferred if more clearly evident) are used to establish the cost bases, except when neither of the values of the assets received or the assets transferred in non-monetary exchanges are determinable within reasonable limits. Valuation techniques consistent with the market approach, income approach and/or cost approach are used to measure fair value. Amortization of finite-lived intangible assets is computed over the useful lives of the respective assets. | ||||||||
f. Impairment of Intangible assets | ||||||||
Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We evaluate intangible assets to determine potential impairment by comparing the carrying amount to the undiscounted estimated future cash flows of the related assets. The Company wrote-off the remaining approximately $200,000 in Granisol product rights during the year ended February 28, 2014. The impairment is presented in discontinued operations. | ||||||||
g. Basic and Diluted Net Loss Per Share | ||||||||
The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. The Company had net losses as of February 28, 2014 and 2013, so the diluted EPS excluded all dilutive potential shares in the diluted EPS because there effect is anti-dilutive. | ||||||||
h. Financial Instruments | ||||||||
ASC 820, Fair Value Measurements (ASC 820) and ASC 825, Financial Instruments (ASC 825) , requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value: | ||||||||
Level 1 - Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. | ||||||||
Level 2 - Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. | ||||||||
Level 3 - Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. | ||||||||
The Company’s financial instruments consist principally of cash, accounts payable, and accrued liabilities. Pursuant to ASC 820 and 825, the fair value of cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. | ||||||||
The Company did not have any financial assets and liabilities measured at fair value on February 28, 2014 and 2013. | ||||||||
i. Revenue Recognition | ||||||||
The Company recognizes revenue in accordance with ASC 605, Revenue Recognition . Revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is provided, and collectability is assured. The Company has had minimal revenue from continuing operations for the years ended February 28, 2014 and none during the year ended February 28, 2013. | ||||||||
j. Recent Accounting Pronouncements | ||||||||
The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. | ||||||||
k. Income Taxes | ||||||||
The Company accounts for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized. | ||||||||
A reconciliation between the income tax expense recognized in the Company's statements of operations and the income tax expense (benefit) computed by applying the domestic federal statutory income tax rate to the net loss for the period for fiscal years 2013 and 2012 is as follows: | ||||||||
February 28, | ||||||||
2014 | 2013 | |||||||
Income tax benefit at federal statutory rate (34% | $ | (258,956 | ) | $ | (107,419 | ) | ||
State income tax benefit | - | (10,918 | ) | |||||
Non-deductible stock based compensation | - | 52,855 | ||||||
Impairment expense | 68,000 | - | ||||||
Change in valuation allowance | 190,956 | 67,000 | ||||||
Other | - | (1,518 | ) | |||||
Total income tax expense | $ | - | $ | - | ||||
As of | ||||||||
February 28, | ||||||||
2014 | 2013 | |||||||
Net operating loss carry-forward | $ | 734,000 | $ | 545,000 | ||||
Other | 299,000 | 299,000 | ||||||
Less: Valuation allowance | (1,033,000 | ) | (844,000 | ) | ||||
Net deferred tax asset | $ | - | $ | - | ||||
The Company had net operating losses of approximately $736,000 that expire in years through 2025. Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carryforwards for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carryforwards may be limited as to use in future years. | ||||||||
l. Share-Based Compensation | ||||||||
The Company accounts for share-based compensation to employees in accordance with Accounting Standards Codification subtopic 718-10, Stock Compensation (“ASC 718-10”) and share-based compensation to non-employees in accordance with ASC 505. These require the measurement and recognition of compensation expense for all share-based payment awards, including stock options based on the estimated fair values. | ||||||||
m. Going Concern | ||||||||
Quint’s financial statements as of February 28, 2014 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Quint has a net loss of $757,403 for the year ended February 28, 2014 and a cumulative deficit $3,247,667 at February 28, 2014. The losses from operations of Quint raise substantial doubt about Quint’s ability to continue as a going concern. | ||||||||
Management cannot provide assurance that Quint will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. Management believes that Quint’s capital resources are not currently adequate to continue operating and maintaining its business strategy for the fiscal year ending February 28, 2015. Quint will seek to raise capital through additional debt and/or equity financings to fund its operations in the future. Although Quint has historically raised capital from sales of equity and from the issuance of promissory notes, there is no assurance that it will be able to continue to do so. If Quint is unable to raise additional capital or secure additional lending in the near future, management expects that Quint will need to curtail or cease operations. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should Quint be unable to continue as a going concern. | ||||||||
Quint is in the process of transitioning to its new operating business and expects to incur operating losses for the next twelve months as it moves forward. This new operating business encompasses entrance into the social discovery aspects of the internet; primarily development of an engagement website with mobile and tablet application. |
Related_Party_Transactions
Related Party Transactions | 12 Months Ended | |
Feb. 28, 2014 | ||
Related Party Transactions [Text Block] | ' | |
3 | Related Party Transactions | |
On March 8, 2013, the Company entered into a Business Development/Advisory Services Agreement with Phys Pharma LLC, a company of which Dr. Durrant is a principal, pursuant to which Phys Pharma agreed to provide the Company a list of select biopharmaceutical companies which might have an interest in acquiring Granisol and assist the Company in marketing and selling Granisol to the prospective purchasers. If the Company sells Granisol to the prospective purchaser introduced by Phys Pharma, the Company agreed to pay Phys Pharma a fee in an amount equal to 20% of the net proceeds received by the Company at closing. | ||
On April 5, 2013, and pursuant to a purchase and sale agreement dated for reference March 5, 2013, Dr. Cameron Durrant, our former President, Chief Executive Officer and director, sold to Constantin Dietrich, a director of our company, 12,750,000 shares of our common stock for total consideration of $51,000. Mr. Dietrich paid the $51,000 purchase price for these shares using cash on hand. In addition, Mr. Dietrich assumed all of Dr. Durrant’s obligations under the Lock-Up Agreement between Dr. Durrant and our company dated February 9, 2011, pursuant to which 8,499,999 of the 12,750,000 shares sold by Dr. Durrant remain “locked up”. Our company has consented to the transfer of the shares and to the assignment and assumption of the obligations under the Lock-Up Agreement. Also on April 5, 2013, and pursuant to a purchase and sale agreement dated for reference March 8, 2013, David Tousley, our former Chief Financial Officer, Secretary, Treasurer and director, sold to Joseph Carusone, our Vice President, Investor Relations and a member of our Board of Directors, 1,200,000 shares of our common stock for total consideration of $9,600. Mr. Carusone paid the $9,600 purchase price for these shares using cash on hand. In addition, Mr. Carusone assumed all of Mr. Tousley’s obligations under the Lock-Up Agreement between Mr. Tousley and our company dated February 9, 2011, pursuant to which 799,998 of the 1,200,000 shares sold by Mr. Tousley remain “locked up”. Our company has consented to the transfer of the shares and to the assignment and assumption of the obligations under the Lock-Up Agreement. | ||
On May 17, 2013, the Company entered into a definitive Web Site Asset Purchase Agreement (the “Agreement”) with Lakefield Media Holding AG and its wholly-owned subsidiary, Flawsome XLerator GmbH (Flawsome). Constantin Dietrich, our current president and director of our company, is the founder and Chief Executive Officer of Lakefield Media Holding AG, which wholly-owns Flawsome.Pursuant to the Agreement, the Company acquired the internet domain name “Slickx.com”, the website and related software, intellectual property rights, accounts, contracts, goodwill and infrastructure for $50,000. This transaction was completed on May 21, 2013. | ||
On May 29, 2013 the Company entered into a consulting agreement with Flawsome, whereby Flawsome agreed to provide certain services, including general management, product management, requirements engineering, quality management, project management, design creation, development team lead, deployment management, content management, reporting services, web development, mobile development, basic content creation, server hosting and monitoring and update services. The agreement expired December 31, 2013, but is continuing on a month-to-month basis. During the year ended February 28, 2014, the Company capitalized $298,800 in development costs contracted through Flawsome related to the “Slickx.com” website and expensed $52,093 in website management expenses. As of February 28, 2014, the Company owes $196,500 to Flawsome. | ||
As of February 28, 2014, the Company owes $30,000 for consulting services to a director and $70,500 to a Company whose shareholder is a director of the Company. Additionally, the Company owes $7,588 to an officer for expenses paid on behalf of the Company. The payables does not bear interest. |
ShortTerm_Notes_Payable
Short-Term Notes Payable | 12 Months Ended | |||||||
Feb. 28, 2014 | ||||||||
Short-Term Notes Payable [Text Block] | ' | |||||||
4 | Short-Term Notes Payable | |||||||
28-Feb-14 | 28-Feb-13 | |||||||
Issued on June 15, 2009, this unsecured promissory note, originally bearing interest at five percent (5% per annum on the principal balance of $50,000, was originally due on June 15, 2011. Effective May 18, 2011 this promissory note was amended whereby the maturity date of the note was extended until February 28, 2013. The promissory note is now past due and the principal amount or such portion thereof as shall remain outstanding from time to time shall accrue simple interest, calculated monthly in arrears, at a rate of 12% per annum commencing on the date of the promissory note and payable at maturity. Effective September 1, 2013, this promissory note was amended whereby the maturity date of the note was extended until June 30, 2014 and the interest rate was reduced to 7% | $ | 50,000 | $ | 50,000 | ||||
Issued on July 26, 2010, this unsecured promissory note, bearing interest at five percent (5% per annum on the principal balance of $200,000, was originally due on July 26, 2011. Effective May 23, 2011 this promissory note was amended whereby the maturity date of the note was extended until February 28, 2013. The promissory note was paid in full in March 2013. | - 0 - | 200,000 | ||||||
Issued on May 6, 2011, this unsecured promissory note, originally bearing interest at five percent (5% per annum on the principal balance of $250,000, was originally due on February 28, 2013. The promissory note is past due and the principal amount or such portion thereof as shall remain outstanding from time to time shall accrue simple interest, calculated monthly in arrears, at a rate of 12% per annum commencing on the date of the promissory note and payable at maturity. Effective September 1, 2013, this promissory note was amended whereby the maturity date of the note was extended until June 30, 2014 and the interest rate was reduced to 7% | 250,000 | 250,000 | ||||||
Issued on September 24, 2013, this unsecured promissory note, bears interest at seven percent (7% per annum on the principal balance of $100,000 and is due on June 30, 2014. | 100,000 | - | ||||||
Issued on February 13, 2014, this unsecured promissory note, bears interest at seven percent (7% per annum on the principal balance of $50,000 and is due on February 13, 2015. | 50,000 | - | ||||||
Total Promissory Notes | $ | 450,000 | $ | 500,000 | ||||
Quint entered into an amendment of a previously amended unsecured promissory note originally dated June 15, 2009 in the principal amount of $50,000. Effective September 1, 2013, the maturity date of the note was extended from December 31, 2012 until June 30, 2014 and the interest rate on the outstanding principal balance was decreased from twelve percent per annum to seven percent per annum. All other terms of the promissory note remain the same. | ||||||||
In addition, as of February 28, 2014, we entered into an amendment of a previously amended unsecured promissory note originally dated May 6, 2011 in the principal amount of $250,000. Effective September 1, 2013, the maturity date of the note was been extended from December 31, 2012 until June 30, 2014 and the interest rate on the outstanding principal balance was decreased from twelve percent per annum to seven percent per annum. All other terms of the promissory note remain the same. | ||||||||
The Company determined that concessions granted in the form of extensions of the due dates and reductions in interest rates on these above mentioned promissory notes are considered debt modifications as defined under Accounting Standards Codification 470-60, “Troubled Debt Restructurings by Debtors”. | ||||||||
Accrued interest on promissory notes payable totaled $76,330 and $78,698 at February 28, 2014 and February 28, 2013, respectively. |
Discontinued_Operations
Discontinued Operations | 12 Months Ended | ||||||||||
Feb. 28, 2014 | |||||||||||
Discontinued Operations [Text Block] | ' | ||||||||||
5 | Discontinued Operations | ||||||||||
During the period ended February 28, 2014, the Company’s management elected to discontinue the operations of its pharmaceutical business, divest itself of the balance of its pharmaceutical assets and engage in the digital media business. As such, all assets, liabilities and expenses of the pharmaceutical business have been presented as discontinued operations in the consolidated financial statements. A summary of those assets and liabilities as of February 28, 2014 and February 28, 2013 and revenues and expenses as of February 28, 2014 and 2012 and from Inception March 18, 2005 through February 28, 2014: | |||||||||||
February 28, | |||||||||||
2014 | 2013 | ||||||||||
Assets from Discontinued Operations | |||||||||||
Accounts receivable, net of reserves | $ | - | $ | 50,556 | |||||||
Intangible assets, net (available for sale) | - | 200,000 | |||||||||
Total Assets | $ | - | $ | 250,556 | |||||||
Liabilities from Discontinued Operations | |||||||||||
Accounts payable and accrued liabilities | $ | 109,449 | $ | 119,382 | |||||||
For the Period | |||||||||||
From Inception | |||||||||||
18-Mar-05 | |||||||||||
Through | |||||||||||
For the Years Ended | February 28, | ||||||||||
February 28, | 2014 | ||||||||||
2014 | 2013 | (Unaudited) | |||||||||
Net Revenues | $ | 1,893 | $ | 77,938 | $ | 1,127,689 | |||||
Expenses | |||||||||||
Cost of goods sold | 1,886 | 52,359 | 359,246 | ||||||||
Amortization expense | - | 86,486 | 226,266 | ||||||||
Consulting fees | 1,619 | 3,333 | 622,069 | ||||||||
Marketing | 2,311 | 33,144 | 629,348 | ||||||||
Write down of mineral property acquisition costs | - | - | 5,000 | ||||||||
Mineral property expenses | - | - | 15,124 | ||||||||
Impairment of product rights | 200,000 | 456,554 | 656,554 | ||||||||
General and administrative | - | 284,651 | 2,342,134 | ||||||||
Total Expenses | 205,816 | 916,527 | 4,855,741 | ||||||||
Other Income | |||||||||||
Gain on sale of product rights | - | - | 64,900 | ||||||||
Other income | 12,442 | 891,965 | 904,407 | ||||||||
Net Income (Loss) From Discontinued Operations | $ | (191,481 | ) | $ | 53,37 6 | $ | (2,758,745 | ) |
Common_Stock_and_Common_Stock_
Common Stock and Common Stock Warrants | 12 Months Ended | ||||||||||
Feb. 28, 2014 | |||||||||||
Common Stock and Common Stock Warrants [Text Block] | ' | ||||||||||
6. Common Stock and Common Stock Warrants | |||||||||||
On November 3, 2010, 1,200,000 units were issued at a purchase price of approximately $0.34 per unit for total cash proceeds of $400,000. Each unit consisted of one share of common stock of the Company and one-half of one share non-detachable purchase warrant. Each whole warrant entitles the holder to purchase one share of common stock at a purchase price of $0.58 per share until November 3, 2012. | |||||||||||
On November 30, 2010, 1,275,000 units were issued at a purchase price of approximately $0.34 per unit for total cash proceeds of $425,000. Each unit consisted of one share of common stock of the Company and one-half of one share non-detachable purchase warrant. Each whole warrant entitles the holder to purchase one share of common stock at a purchase price of $0.58 per share until November 30, 2012. | |||||||||||
On November 30, 2010, 615,000 units were issued at a purchase price of approximately $0.33 per unit for cancellation of a promissory note in the principal amount of $200,000 plus accrued interest of $5,000. Each unit consisted of one share of common stock of the Company and one-half of one share non-detachable purchase warrant. Each whole warrant entitles the holder to purchase one share of common stock at a purchase price of $0.58 per share until November 30, 2012. | |||||||||||
On November 25, 2013, the Company sold 375,000 units of our securities at a price of $0.20 per unit for gross proceeds of $75,000. Each unit consists of one share of common stock and one non-transferable common stock purchase warrant, with each common stock purchase warrant entitling the holder to acquire one additional share of our common stock at a price of $0.50 per share for a period of 60 months. | |||||||||||
The following table summarizes the outstanding warrants and associated activity for the years ended February 28, 2014 and 2013: | |||||||||||
Weighted | |||||||||||
Average | |||||||||||
Number of | Remaining | ||||||||||
Warrants | Weighted | Contractual | |||||||||
Outstanding | Average Price | Life | |||||||||
Balance, February 29, 2012 | - | - | - | ||||||||
Granted | - | - | - | ||||||||
Exercised | - | - | - | ||||||||
Expired | - | - | - | ||||||||
Balance, February 28, 2013 | - | - | - | ||||||||
Granted | 375,000 | 0.5 | 6 | ||||||||
Exercised | - | - | - | ||||||||
Expired | - | - | - | ||||||||
Balance, February 28, 2014 | 375,000 | $ | 0.5 | 4.74 | |||||||
The aggregate intrinsic value of outstanding warrants was $78,713 and $0 as of February 28, 2014 and 2013, respectively. |
Stock_Options
Stock Options | 12 Months Ended | |||||||
Feb. 28, 2014 | ||||||||
Stock Options [Text Block] | ' | |||||||
7 | Stock Options | |||||||
Effective February 18, 2011, the Board of Directors adopted and approved the 2011 stock option plan. The purpose of the 2011 stock option plan is to enhance the long-term stockholder value of the Company by offering opportunities to directors, key employees, officers, independent contractors and consultants of the company to acquire and maintain stock ownership in the company in order to give these persons the opportunity to participate in the company's growth and success, and to encourage them to remain in the service of the company. A total of 6,000,000 shares of our common stock are available for issuance and during the twelve-month period after the first anniversary of the adoption of the 2011 stock option plan by the Board of Directors. During each twelve-month period thereafter, the Board of Directors is authorized to increase the number of shares issuable by up to 1,500,000 shares. | ||||||||
A summary of the status of the Company's outstanding stock option activity for the twelve months ended February 28, 2013 and 2014 is as follows: | ||||||||
Weighted | ||||||||
Average | ||||||||
Number of | Exercise | |||||||
Options | Price | |||||||
Balance, February 29, 2012 | 2,662,500 | $ | 0.38 | |||||
Issued | - | - | ||||||
Cancelled | (2,662,500 | ) | 0.38 | |||||
Balance, February 28, 2013 | - | - | ||||||
Issued | - | - | ||||||
Cancelled | - | - | ||||||
Balance, February 28, 2014 | - | $ | - | |||||
As of February 28, 2013, unrecognized compensation costs related to non-vested stock option awards totaled $306,189. During the year ended February 28, 2013, unrecognized compensation costs was reduced by approximately $178,000 for estimated forfeitures of unvested stock options as a result of notice provided to Mr. Tousley of termination of his employment agreement effective October 31, 2012. On May 23, 2012, the Company agreed with all option holders to cancel any and all options outstanding as of that date. As a result, the Company expensed all unrecognized compensation costs as of the cancelation date. Total stock-based compensation expense for the year ended February 28, 2013 was $132,138. |
Subsequent_Events
Subsequent Events | 12 Months Ended | |
Feb. 28, 2014 | ||
Subsequent Events [Text Block] | ' | |
8 | Subsequent Events | |
On March 31, 2014, the Company accepted a subscription from one non-US investor and issued a promissory note in the amount of $75,000. The promissory note is payable in full at maturity on March 31, 2015, and the principal amount or such portion thereof as shall remain outstanding from time to time accrues simple interest, calculated monthly, at a rate of 7% per annum commencing on the date of the promissory note. |
Summary_of_Significant_Account1
Summary of Significant Accounting Policies (Policies) | 12 Months Ended | |||||||
Feb. 28, 2014 | ||||||||
Basis of Presentation and Accounting Methods [Policy Text Block] | ' | |||||||
a. Basis of Presentation and Accounting Methods | ||||||||
The financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States using the accrual method of accounting. The Company’s fiscal year-end is February 28. | ||||||||
Use of estimates [Policy Text Block] | ' | |||||||
b. Use of Estimates | ||||||||
The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. | ||||||||
Reclassification [Policy Text Block] | ' | |||||||
c. Reclassification | ||||||||
Certain prior year amounts have been reclassified to conform to the current year presentation. | ||||||||
Cash and Cash Equivalents [Policy Text Block] | ' | |||||||
d. Cash and Cash Equivalents | ||||||||
The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. As of February 28, 2014 and 2013, the Company had no cash equivalents. | ||||||||
Intangible Assets [Policy Text Block] | ' | |||||||
e. Intangible Assets | ||||||||
Acquired intangible assets other than goodwill are amortized over their useful lives unless the lives are determined to be indefinite. Acquired intangible assets are carried at cost, less accumulated amortization. For intangible assets purchased in a business combination or received in a non-monetary exchange, the estimated fair values of the assets received (or, for non-monetary exchanges, the estimated fair values of the assets transferred if more clearly evident) are used to establish the cost bases, except when neither of the values of the assets received or the assets transferred in non-monetary exchanges are determinable within reasonable limits. Valuation techniques consistent with the market approach, income approach and/or cost approach are used to measure fair value. Amortization of finite-lived intangible assets is computed over the useful lives of the respective assets. | ||||||||
Impairment of Intangible assets [Policy Text Block] | ' | |||||||
f. Impairment of Intangible assets | ||||||||
Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We evaluate intangible assets to determine potential impairment by comparing the carrying amount to the undiscounted estimated future cash flows of the related assets. The Company wrote-off the remaining approximately $200,000 in Granisol product rights during the year ended February 28, 2014. The impairment is presented in discontinued operations. | ||||||||
Basic and diluted net loss per share [Policy Text Block] | ' | |||||||
g. Basic and Diluted Net Loss Per Share | ||||||||
The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. The Company had net losses as of February 28, 2014 and 2013, so the diluted EPS excluded all dilutive potential shares in the diluted EPS because there effect is anti-dilutive. | ||||||||
Financial Instruments [Policy Text Block] | ' | |||||||
h. Financial Instruments | ||||||||
ASC 820, Fair Value Measurements (ASC 820) and ASC 825, Financial Instruments (ASC 825) , requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value: | ||||||||
Level 1 - Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. | ||||||||
Level 2 - Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. | ||||||||
Level 3 - Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. | ||||||||
The Company’s financial instruments consist principally of cash, accounts payable, and accrued liabilities. Pursuant to ASC 820 and 825, the fair value of cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. | ||||||||
The Company did not have any financial assets and liabilities measured at fair value on February 28, 2014 and 2013. | ||||||||
Revenue Recognition [Policy Text Block] | ' | |||||||
i. Revenue Recognition | ||||||||
The Company recognizes revenue in accordance with ASC 605, Revenue Recognition . Revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is provided, and collectability is assured. The Company has had minimal revenue from continuing operations for the years ended February 28, 2014 and none during the year ended February 28, 2013. | ||||||||
Recent Accounting Pronouncements [Policy Text Block] | ' | |||||||
j. Recent Accounting Pronouncements | ||||||||
The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. | ||||||||
Income Taxes [Policy Text Block] | ' | |||||||
k. Income Taxes | ||||||||
The Company accounts for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized. | ||||||||
A reconciliation between the income tax expense recognized in the Company's statements of operations and the income tax expense (benefit) computed by applying the domestic federal statutory income tax rate to the net loss for the period for fiscal years 2013 and 2012 is as follows: | ||||||||
February 28, | ||||||||
2014 | 2013 | |||||||
Income tax benefit at federal statutory rate (34% | $ | (258,956 | ) | $ | (107,419 | ) | ||
State income tax benefit | - | (10,918 | ) | |||||
Non-deductible stock based compensation | - | 52,855 | ||||||
Impairment expense | 68,000 | - | ||||||
Change in valuation allowance | 190,956 | 67,000 | ||||||
Other | - | (1,518 | ) | |||||
Total income tax expense | $ | - | $ | - | ||||
As of | ||||||||
February 28, | ||||||||
2014 | 2013 | |||||||
Net operating loss carry-forward | $ | 734,000 | $ | 545,000 | ||||
Other | 299,000 | 299,000 | ||||||
Less: Valuation allowance | (1,033,000 | ) | (844,000 | ) | ||||
Net deferred tax asset | $ | - | $ | - | ||||
The Company had net operating losses of approximately $736,000 that expire in years through 2025. Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carryforwards for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carryforwards may be limited as to use in future years. | ||||||||
Share-Based Compensation [Policy Text Block] | ' | |||||||
l. Share-Based Compensation | ||||||||
The Company accounts for share-based compensation to employees in accordance with Accounting Standards Codification subtopic 718-10, Stock Compensation (“ASC 718-10”) and share-based compensation to non-employees in accordance with ASC 505. These require the measurement and recognition of compensation expense for all share-based payment awards, including stock options based on the estimated fair values. | ||||||||
Going Concern [Policy Text Block] | ' | |||||||
m. Going Concern | ||||||||
Quint’s financial statements as of February 28, 2014 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Quint has a net loss of $757,403 for the year ended February 28, 2014 and a cumulative deficit $3,247,667 at February 28, 2014. The losses from operations of Quint raise substantial doubt about Quint’s ability to continue as a going concern. | ||||||||
Management cannot provide assurance that Quint will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. Management believes that Quint’s capital resources are not currently adequate to continue operating and maintaining its business strategy for the fiscal year ending February 28, 2015. Quint will seek to raise capital through additional debt and/or equity financings to fund its operations in the future. Although Quint has historically raised capital from sales of equity and from the issuance of promissory notes, there is no assurance that it will be able to continue to do so. If Quint is unable to raise additional capital or secure additional lending in the near future, management expects that Quint will need to curtail or cease operations. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should Quint be unable to continue as a going concern. | ||||||||
Quint is in the process of transitioning to its new operating business and expects to incur operating losses for the next twelve months as it moves forward. This new operating business encompasses entrance into the social discovery aspects of the internet; primarily development of an engagement website with mobile and tablet application. |
Summary_of_Significant_Account2
Summary of Significant Accounting Policies (Tables) | 12 Months Ended | |||||||
Feb. 28, 2014 | ||||||||
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | ' | |||||||
February 28, | ||||||||
2014 | 2013 | |||||||
Income tax benefit at federal statutory rate (34% | $ | (258,956 | ) | $ | (107,419 | ) | ||
State income tax benefit | - | (10,918 | ) | |||||
Non-deductible stock based compensation | - | 52,855 | ||||||
Impairment expense | 68,000 | - | ||||||
Change in valuation allowance | 190,956 | 67,000 | ||||||
Other | - | (1,518 | ) | |||||
Total income tax expense | $ | - | $ | - | ||||
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | ' | |||||||
As of | ||||||||
February 28, | ||||||||
2014 | 2013 | |||||||
Net operating loss carry-forward | $ | 734,000 | $ | 545,000 | ||||
Other | 299,000 | 299,000 | ||||||
Less: Valuation allowance | (1,033,000 | ) | (844,000 | ) | ||||
Net deferred tax asset | $ | - | $ | - |
ShortTerm_Notes_Payable_Tables
Short-Term Notes Payable (Tables) | 12 Months Ended | |||||||
Feb. 28, 2014 | ||||||||
Schedule of Debt [Table Text Block] | ' | |||||||
28-Feb-14 | 28-Feb-13 | |||||||
Issued on June 15, 2009, this unsecured promissory note, originally bearing interest at five percent (5% per annum on the principal balance of $50,000, was originally due on June 15, 2011. Effective May 18, 2011 this promissory note was amended whereby the maturity date of the note was extended until February 28, 2013. The promissory note is now past due and the principal amount or such portion thereof as shall remain outstanding from time to time shall accrue simple interest, calculated monthly in arrears, at a rate of 12% per annum commencing on the date of the promissory note and payable at maturity. Effective September 1, 2013, this promissory note was amended whereby the maturity date of the note was extended until June 30, 2014 and the interest rate was reduced to 7% | $ | 50,000 | $ | 50,000 | ||||
Issued on July 26, 2010, this unsecured promissory note, bearing interest at five percent (5% per annum on the principal balance of $200,000, was originally due on July 26, 2011. Effective May 23, 2011 this promissory note was amended whereby the maturity date of the note was extended until February 28, 2013. The promissory note was paid in full in March 2013. | - 0 - | 200,000 | ||||||
Issued on May 6, 2011, this unsecured promissory note, originally bearing interest at five percent (5% per annum on the principal balance of $250,000, was originally due on February 28, 2013. The promissory note is past due and the principal amount or such portion thereof as shall remain outstanding from time to time shall accrue simple interest, calculated monthly in arrears, at a rate of 12% per annum commencing on the date of the promissory note and payable at maturity. Effective September 1, 2013, this promissory note was amended whereby the maturity date of the note was extended until June 30, 2014 and the interest rate was reduced to 7% | 250,000 | 250,000 | ||||||
Issued on September 24, 2013, this unsecured promissory note, bears interest at seven percent (7% per annum on the principal balance of $100,000 and is due on June 30, 2014. | 100,000 | - | ||||||
Issued on February 13, 2014, this unsecured promissory note, bears interest at seven percent (7% per annum on the principal balance of $50,000 and is due on February 13, 2015. | 50,000 | - | ||||||
Total Promissory Notes | $ | 450,000 | $ | 500,000 |
Discontinued_Operations_Tables
Discontinued Operations (Tables) | 12 Months Ended | ||||||||||
Feb. 28, 2014 | |||||||||||
Schedule of Disposal Groups, Including Discontinued Operations, Balance Sheet Disclosures [Table Text Block] | ' | ||||||||||
February 28, | |||||||||||
2014 | 2013 | ||||||||||
Assets from Discontinued Operations | |||||||||||
Accounts receivable, net of reserves | $ | - | $ | 50,556 | |||||||
Intangible assets, net (available for sale) | - | 200,000 | |||||||||
Total Assets | $ | - | $ | 250,556 | |||||||
Liabilities from Discontinued Operations | |||||||||||
Accounts payable and accrued liabilities | $ | 109,449 | $ | 119,382 | |||||||
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement Disclosures [Table Text Block] | ' | ||||||||||
For the Period | |||||||||||
From Inception | |||||||||||
18-Mar-05 | |||||||||||
Through | |||||||||||
For the Years Ended | February 28, | ||||||||||
February 28, | 2014 | ||||||||||
2014 | 2013 | (Unaudited) | |||||||||
Net Revenues | $ | 1,893 | $ | 77,938 | $ | 1,127,689 | |||||
Expenses | |||||||||||
Cost of goods sold | 1,886 | 52,359 | 359,246 | ||||||||
Amortization expense | - | 86,486 | 226,266 | ||||||||
Consulting fees | 1,619 | 3,333 | 622,069 | ||||||||
Marketing | 2,311 | 33,144 | 629,348 | ||||||||
Write down of mineral property acquisition costs | - | - | 5,000 | ||||||||
Mineral property expenses | - | - | 15,124 | ||||||||
Impairment of product rights | 200,000 | 456,554 | 656,554 | ||||||||
General and administrative | - | 284,651 | 2,342,134 | ||||||||
Total Expenses | 205,816 | 916,527 | 4,855,741 | ||||||||
Other Income | |||||||||||
Gain on sale of product rights | - | - | 64,900 | ||||||||
Other income | 12,442 | 891,965 | 904,407 | ||||||||
Net Income (Loss) From Discontinued Operations | $ | (191,481 | ) | $ | 53,37 6 | $ | (2,758,745 | ) |
Common_Stock_and_Common_Stock_1
Common Stock and Common Stock Warrants (Tables) | 12 Months Ended | ||||||||||
Feb. 28, 2014 | |||||||||||
Schedule of Purchase Warrant Activity [Table Text Block] | ' | ||||||||||
Weighted | |||||||||||
Average | |||||||||||
Number of | Remaining | ||||||||||
Warrants | Weighted | Contractual | |||||||||
Outstanding | Average Price | Life | |||||||||
Balance, February 29, 2012 | - | - | - | ||||||||
Granted | - | - | - | ||||||||
Exercised | - | - | - | ||||||||
Expired | - | - | - | ||||||||
Balance, February 28, 2013 | - | - | - | ||||||||
Granted | 375,000 | 0.5 | 6 | ||||||||
Exercised | - | - | - | ||||||||
Expired | - | - | - | ||||||||
Balance, February 28, 2014 | 375,000 | $ | 0.5 | 4.74 |
Stock_Options_Tables
Stock Options (Tables) | 12 Months Ended | |||||||
Feb. 28, 2014 | ||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | |||||||
Weighted | ||||||||
Average | ||||||||
Number of | Exercise | |||||||
Options | Price | |||||||
Balance, February 29, 2012 | 2,662,500 | $ | 0.38 | |||||
Issued | - | - | ||||||
Cancelled | (2,662,500 | ) | 0.38 | |||||
Balance, February 28, 2013 | - | - | ||||||
Issued | - | - | ||||||
Cancelled | - | - | ||||||
Balance, February 28, 2014 | - | $ | - |
Nature_of_Operations_and_Conti1
Nature of Operations and Continuance of Business (Narrative) (Details) (USD $) | 1 Months Ended | 12 Months Ended | 107 Months Ended | 1 Months Ended | 1 Months Ended | 1 Months Ended | |||||||||
Aug. 31, 2013 | Feb. 28, 2014 | Feb. 28, 2013 | Feb. 28, 2014 | Aug. 07, 2013 | Aug. 06, 2013 | Jun. 30, 2012 | Feb. 29, 2012 | Jul. 16, 2012 | Jun. 27, 2012 | Jul. 31, 2012 | Feb. 29, 2012 | Feb. 21, 2012 | Feb. 29, 2012 | Feb. 29, 2012 | |
Apricus [Member] | Apricus [Member] | Apricus [Member] | Apricus [Member] | Apricus [Member] | Apricus [Member] | Apricus [Member] | Apricus [Member] | Apricus [Member] | |||||||
Maximum [Member] | Contemplated Merger [Member] | Contemplated Merger [Member] | Contemplated Merger [Member] | Contemplated Merger [Member] | |||||||||||
Amounts distributed to shareholders [Member] | Amounts distributed to CEO and CFO [Member] | ||||||||||||||
Proceeds from Sale of Intangible Assets | ' | ' | ' | ' | ' | ' | ' | $325,000 | ' | ' | ' | ' | ' | ' | ' |
Proceeds From Sale Of Rights | ' | ' | ' | ' | ' | ' | ' | 260,000 | ' | ' | ' | ' | ' | ' | ' |
Gain (Loss) on Disposition of Intangible Assets | ' | ' | ' | ' | ' | ' | ' | 65,000 | ' | ' | ' | ' | ' | ' | ' |
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,000,000 | ' | 3,600,000 | 400,000 |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 675,000 | ' | ' |
Value of restricted stock to be paid if the two companies do not merge by June 1, 2012 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | ' | ' |
Shares Issued and Delivered to Company | ' | ' | ' | ' | ' | ' | ' | ' | ' | 373,134 | ' | ' | ' | ' | ' |
Proceeds from Issuance of Common Stock | ' | 75,000 | 0 | 2,060,000 | ' | ' | 1,000,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Other Income | ' | ' | ' | ' | ' | ' | 1,000,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Average daily volume of the common stock traded in the previous five trading days | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5.00% | ' | ' | ' | ' |
Investment Owned, at Fair Value | ' | ' | ' | ' | ' | ' | ' | ' | $1,000,000 | ' | ' | ' | ' | ' | ' |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 3 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common Stock, Shares Authorized | ' | 450,000,000 | 450,000,000 | 450,000,000 | 450,000,000 | 150,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common Stock, Shares, Issued | ' | 62,883,000 | 62,508,000 | 62,883,000 | 62,508,000 | 20,836,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common Stock, Shares, Outstanding | ' | 62,883,000 | 62,508,000 | 62,883,000 | 62,508,000 | 20,836,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Summary_of_Significant_Account3
Summary of Significant Accounting Policies (Narrative) (Details) (USD $) | 12 Months Ended | 107 Months Ended | ||||||||
Feb. 28, 2006 | Feb. 28, 2014 | Feb. 28, 2013 | Feb. 29, 2012 | Feb. 28, 2011 | Feb. 28, 2010 | Feb. 28, 2009 | Feb. 29, 2008 | Feb. 28, 2007 | Feb. 28, 2014 | |
Intangible asset, impairment charge | ' | $200,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Operating Loss Carryforwards | ' | 736,000 | ' | ' | ' | ' | ' | ' | ' | 736,000 |
Net Loss | 21,237 | 757,403 | 315,938 | 952,543 | 1,049,087 | 58,201 | 53,957 | 65,411 | 50,890 | 3,324,667 |
Accumulative Deficit | ' | $3,247,667 | ' | ' | ' | ' | ' | ' | ' | $3,247,667 |
Related_Party_Transactions_Nar
Related Party Transactions (Narrative) (Details) (USD $) | 12 Months Ended | 107 Months Ended | 1 Months Ended | 12 Months Ended | |||||||
Feb. 28, 2014 | Feb. 28, 2013 | Feb. 28, 2014 | 31-May-13 | Mar. 31, 2013 | Apr. 30, 2013 | Apr. 30, 2013 | Feb. 28, 2014 | Feb. 28, 2014 | Feb. 28, 2014 | Feb. 28, 2014 | |
Acquisition of Slickx [Member] | Phys Pharma LLC [Member] | Mr. Carusone [Member] | Mr. Dietrich [Member] | Flawsome [Member] | Director [Member] | A Company whose shareholder is a director of the Company [Member] | Officer [Member] | ||||
Website Development [Member] | Consulting [Member] | ||||||||||
Referral fee percent | ' | ' | ' | ' | 20.00% | ' | ' | ' | ' | ' | ' |
Stock Issued During Period, Shares, Issued for Cash | ' | ' | ' | ' | ' | 1,200,000 | 12,750,000 | ' | ' | ' | ' |
Stock Issued During Period, Value, Issued for Cash | ' | ' | ' | ' | ' | $9,600 | $51,000 | ' | ' | ' | ' |
Common stock, locked-up | ' | ' | ' | ' | ' | 799,998 | 8,499,999 | ' | ' | ' | ' |
Acquisition of SlickX and Flawsome | 50,000 | 0 | 50,000 | 50,000 | ' | ' | ' | ' | ' | ' | ' |
Website and website development cost | 331,360 | 0 | 331,360 | ' | ' | ' | ' | 298,800 | ' | ' | ' |
Website operations and maintenance | 52,093 | 0 | 52,093 | ' | ' | ' | ' | 52,093 | ' | ' | ' |
Due to Related Parties, Current | ' | ' | ' | ' | ' | ' | ' | $196,500 | $30,000 | $70,500 | $7,588 |
ShortTerm_Notes_Payable_Narrat
Short-Term Notes Payable (Narrative) (Details) (USD $) | Feb. 28, 2014 | Feb. 28, 2013 | Feb. 28, 2014 | Feb. 28, 2013 | Jun. 15, 2009 | Feb. 28, 2014 | Feb. 28, 2013 | 6-May-11 |
Unsecured Promissory Note Issued on June 15, 2009 [Member] | Unsecured Promissory Note Issued on June 15, 2009 [Member] | Unsecured Promissory Note Issued on June 15, 2009 [Member] | Unsecured Promissory Note Issued on May 6, 2011 [Member] | Unsecured Promissory Note Issued on May 6, 2011 [Member] | Unsecured Promissory Note Issued on May 6, 2011 [Member] | |||
Promissory notes | $450,000 | $500,000 | $50,000 | $50,000 | $50,000 | $250,000 | $250,000 | $250,000 |
Debt Instrument, Interest Rate, Stated Percentage | ' | ' | 7.00% | 12.00% | -5.00% | 7.00% | 12.00% | -5.00% |
Accrued interest on promissory notes payable | $76,330 | $78,698 | ' | ' | ' | ' | ' | ' |
Common_Stock_and_Common_Stock_2
Common Stock and Common Stock Warrants (Narrative) (Details) (USD $) | 1 Months Ended | 1 Months Ended | ||||
Nov. 30, 2013 | Feb. 28, 2014 | Feb. 28, 2013 | Nov. 30, 2010 | Nov. 30, 2010 | Nov. 30, 2010 | |
First Issuance [Member] | Second Issuance [Member] | Third Issuance [Member] | ||||
Units issued | 375,000 | ' | ' | 1,200,000 | 1,275,000 | 615,000 |
Price per unit | $0.20 | ' | ' | $0.34 | $0.34 | $0.33 |
Proceeds from units issued | $75,000 | ' | ' | $400,000 | $425,000 | $200,000 |
Price per share | $0.50 | ' | ' | $0.58 | $0.58 | $0.58 |
Accrued interest | ' | ' | ' | ' | ' | 5,000 |
Class of Warrant or Right, Grants in Period, Contractual Term | '60 years | ' | ' | ' | ' | ' |
Outstanding Warrants, Aggregate Intrinsic Value | ' | $78,713 | $0 | ' | ' | ' |
Stock_Options_Narrative_Detail
Stock Options (Narrative) (Details) (USD $) | 12 Months Ended | 107 Months Ended | ||
Feb. 28, 2014 | Feb. 28, 2013 | Feb. 29, 2012 | Feb. 28, 2014 | |
Common Stock, Capital Shares Reserved for Future Issuance | 6,000,000 | ' | ' | 6,000,000 |
Common Stock, Maximum Authorized Increase of Capital Shares Reserved for Future Issuance | 1,500,000 | ' | ' | 1,500,000 |
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options | ' | $306,189 | ' | ' |
Decrease In Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options | ' | 178,000 | ' | ' |
Stock based compensation | $0 | $132,138 | $213,912 | $346,050 |
Subsequent_Events_Narrative_De
Subsequent Events (Narrative) (Details) (Subsequent Event [Member], USD $) | 12 Months Ended |
Feb. 28, 2014 | |
Subsequent Event [Member] | ' |
Notes Issued | $75,000 |
Debt Instrument, Interest Rate, Stated Percentage | 7.00% |
Schedule_of_Components_of_Inco
Schedule of Components of Income Tax Expense (Benefit) (Details) (USD $) | 12 Months Ended | |
Feb. 28, 2014 | Feb. 28, 2013 | |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | -34.00% | 34.00% |
Income tax benefit at federal statutory rate | ($258,956) | ($107,419) |
State income tax benefit | 0 | -10,918 |
Non-deductible stock based compensation | 0 | 52,855 |
Impairment Expense | 68,000 | 0 |
Change in valuation allowance | 190,956 | 67,000 |
Other | 0 | -1,518 |
Total income tax expense | $0 | $0 |
Schedule_of_Deferred_Tax_Asset
Schedule of Deferred Tax Assets and Liabilities (Details) (USD $) | Feb. 28, 2014 | Feb. 28, 2013 |
Net operating loss carry-forward | $734,000 | $545,000 |
Other | 299,000 | 299,000 |
Less: Valuation allowance | -1,033,000 | -844,000 |
Net deferred tax asset | $0 | $0 |
Schedule_of_Debt_Details
Schedule of Debt (Details) (USD $) | Feb. 28, 2014 | Feb. 28, 2013 | Feb. 28, 2014 | Feb. 28, 2013 | Jun. 15, 2009 | Feb. 28, 2014 | Feb. 28, 2013 | Jul. 26, 2010 | Feb. 28, 2014 | Feb. 28, 2013 | 6-May-11 | Feb. 28, 2014 | Sep. 24, 2013 | Feb. 28, 2013 | Feb. 28, 2014 | Feb. 13, 2014 | Feb. 28, 2013 |
Unsecured Promissory Note Issued on June 15, 2009 [Member] | Unsecured Promissory Note Issued on June 15, 2009 [Member] | Unsecured Promissory Note Issued on June 15, 2009 [Member] | Unsecured Promissory Note Issued on July 26, 2010 [Member] | Unsecured Promissory Note Issued on July 26, 2010 [Member] | Unsecured Promissory Note Issued on July 26, 2010 [Member] | Unsecured Promissory Note Issued on May 6, 2011 [Member] | Unsecured Promissory Note Issued on May 6, 2011 [Member] | Unsecured Promissory Note Issued on May 6, 2011 [Member] | Unsecured Promissory Note Issued on September 24, 2013 [Member] | Unsecured Promissory Note Issued on September 24, 2013 [Member] | Unsecured Promissory Note Issued on September 24, 2013 [Member] | Unsecured Promissory Note Issued on February 13, 2014 [Member] | Unsecured Promissory Note Issued on February 13, 2014 [Member] | Unsecured Promissory Note Issued on February 13, 2014 [Member] | |||
Debt Instrument, Interest Rate, Stated Percentage | ' | ' | 7.00% | 12.00% | -5.00% | ' | ' | -5.00% | 7.00% | 12.00% | -5.00% | ' | -7.00% | ' | ' | -7.00% | ' |
Promissory notes | $450,000 | $500,000 | $50,000 | $50,000 | $50,000 | $0 | $200,000 | $200,000 | $250,000 | $250,000 | $250,000 | $100,000 | $100,000 | $0 | $50,000 | $50,000 | $0 |
Schedule_of_Disposal_Groups_In
Schedule of Disposal Groups, Including Discontinued Operations, Balance Sheet Disclosures (Details) (USD $) | Feb. 28, 2014 | Feb. 28, 2013 |
Accounts receivable, net of reserves | $0 | $50,556 |
Intangible assets, net (available for sale) | 0 | 200,000 |
Total Assets | 0 | 250,556 |
Accounts payable and accrued liabilities | $109,449 | $119,382 |
Schedule_of_Disposal_Groups_In1
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement Disclosures (Details) (USD $) | 12 Months Ended | 107 Months Ended | |
Feb. 28, 2014 | Feb. 28, 2013 | Feb. 28, 2014 | |
Net revenues | $1,893 | $77,938 | $1,127,689 |
Cost of goods sold | 1,886 | 52,359 | 359,246 |
Amortization expense | 0 | 86,486 | 226,266 |
Consulting fees | 1,619 | 3,333 | 622,069 |
Marketing | 2,311 | 33,144 | 629,348 |
Write down of mineral property acquisition costs | 0 | 0 | 5,000 |
Mineral property expenses | 0 | 0 | 15,124 |
Impairment of product rights | 200,000 | 456,554 | 656,554 |
General and administrative | 0 | 284,651 | 2,342,134 |
Total Expenses | 205,816 | 916,527 | 4,855,741 |
Gain on sale of product rights | 0 | 0 | 64,900 |
Other income | 12,442 | 891,965 | 904,407 |
Net Income (Loss) From Discontinued Operations | ($191,481) | $53,376 | ($2,758,745) |
Schedule_of_Purchase_Warrant_A
Schedule of Purchase Warrant Activity (Details) (USD $) | 12 Months Ended | |
Feb. 28, 2014 | Feb. 28, 2013 | |
Class of Warrant or Right, Outstanding, Beginning of Period | 0 | 0 |
Class of Warrant or Right, Outstanding Exercise Price, Beginning of Period | $0 | $0 |
Class of Warrant or Right, Weighted Average Remaining Contractual Term, Beginning of Period | '0 years | '0 years |
Class of Warrant or Right, Number of Warrants Issued | 375,000 | 0 |
Class of Warrant or Right, Exercise Price of Warrants Issued | $0.50 | $0 |
Class of Warrant or Right, Warrants Issued, Weighted Average Remaining Contractual Term | '6 years | '0 years |
Class of Warrant or Right, Exercises in Period | 0 | 0 |
Class of Warrant or Right, Exercises in Period, Weighted Average Exercise Price | $0 | $0 |
Class of Warrant or Right, Exercises in Period, Weighted Average Remaining Contractual Term | '0 years | '0 years |
Class of Warrant or Right, Expirations in Period | 0 | 0 |
Class of Warrant or Right, Expirations in Period, Weighted Average Exercise Price | $0 | $0 |
Class of Warrant or Right, Expirations in Period, Weighted Average Remaining Contractual Term | '0 years | '0 years |
Class of Warrant or Right, Outstanding, End of Period | 375,000 | 0 |
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price, End of Period | $0.50 | $0 |
Class of Warrant or Right, Weighted Average Remaining Contractual Term, End of Period | '4 years 8 months 26 days | '0 years |
Schedule_of_Sharebased_Compens
Schedule of Share-based Compensation, Stock Options, Activity (Details) (USD $) | 12 Months Ended | |
Feb. 28, 2014 | Feb. 28, 2013 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 0 | 2,662,500 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $0 | $0.38 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Issued in Period | 0 | 0 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Issued in Period, Weighted Average Exercise Price | $0 | $0 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | 0 | -2,662,500 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | $0 | $0.38 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, End of Period | 0 | 0 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, End of Period | $0 | $0 |